Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Recent Street research on MiMedx Group has centered on trimming price targets by US$1 to US$5 at a time, as analysts recheck their assumptions. Those smaller step downs, whether bullish or bearish, line up with commentary that suggests many analysts are fine tuning their views on profitability and execution rather than completely rethinking the stock. As you read on, you will see how to track these price target moves and what they might signal for the evolving narrative around MiMedx Group.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Across recent notes, Craig Hallum, Lake Street, Northland and Citizens have mostly made incremental price target adjustments, which signals that their core views on MiMedx Group's business model and long term potential are intact rather than being reset.
-
The clustering of research around April 2026 suggests MiMedx remains on the radar of multiple firms, giving you a range of institutional perspectives on valuation, execution and growth prospects to track over time.
🐻 Bearish Takeaways
-
Lake Street cut its price target by US$5, one of the larger moves in the recent set of reports, which points to increased caution on how MiMedx is priced relative to its fundamentals.
-
Citizens reduced its target twice in April, first by US$3 and later by US$1, which indicates a step down in expectations around execution or growth assumptions used in its models.
-
Northland's US$4 target cut adds to the overall tone of trimmed expectations, reinforcing that several firms are reassessing how much upside they are willing to underwrite at current levels.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for MiMedx Group. See which could impact your investment.
What's in the News
-
MiMedx Group launched G4Derm Plus, an acellular flowable ECM product for complex wound management, with initial sales already reaching customers across the U.S.
-
The company secured exclusive U.S. distribution rights for G4Derm Plus. It added a peptide matrix product aimed at surgical markets and supporting use across hospital networks.
-
MiMedx Group signed multiple group purchasing organization agreements for G4Derm Plus, including Premier and Vizient, allowing a national launch across participating hospitals.
-
The company launched CHORIOFIX, a lyophilized human placental allograft for acute and chronic wounds, and added it to the CAMPAIGN trial. It also revised full year 2026 net sales guidance to US$260 million to US$290 million due to disruption in the wound care market.
How This Changes the Fair Value For MiMedx Group
-
Fair value in the model holds at US$6.50 per share, with no change in this update.
-
Long term revenue growth is effectively unchanged, with an assumed decline of about 3.55%.
-
Net profit margin moves from 5.15% to 2.46% in the model.
-
The future P/E multiple used in the model moves from 67.6x to 140.4x.
-
The discount rate moves slightly from 7.17% to 7.16%.
Never Miss an Update: Follow The Narrative
Narratives link a company's story to a financial forecast and fair value, so you can see how clinical, regulatory, and commercial developments feed into the numbers. They update as new data comes in, helping you keep track of what has actually changed in the investment case.
Head over to the Simply Wall St Community and follow the Narrative on MiMedx Group to stay up to date on:
-
How chronic disease trends and an aging population shape demand for MiMedx Group's placental allograft and advanced wound care products.
-
What new products, clinical trials, and manufacturing efficiencies could mean for revenue mix and margins over time.
-
How Medicare reimbursement reforms, possible market contraction in skin substitutes, and concentrated exposure to placental derived products could affect revenue stability and earnings power.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MDXG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
